C57BL/6N-Tg(Vav1-STAT5B*N642H)726Biat/Biat
| Status | Available to order |
| EMMA ID | EM:12475 |
| International strain name | C57BL/6N-Tg(Vav1-STAT5B*N642H)726Biat/Biat |
| Alternative name | B6N-Tg(STAT5BN/H)726Biat |
| Strain type | Transgenic Strains |
| Allele/Transgene symbol | Tg(Vav1-STAT5B*N642H)726Biat |
| Gene/Transgene symbol | Tg(Vav1-STAT5B*N642H)726Biat |
Information from provider
| Provider | Richard Moriggl |
| Provider affiliation | Department for Biomedical Sciences, University of Veterinary Medicine, Vienna (Vetmeduni Vienna) |
| Genetic information | Transgenic mice were generated and bred on a C57BL/6NCrl background. We used the Vav1-hematopoietic vector Vav1-hCD4 (HS21/45) to generate several transgenic mouse lines expressing hSTAT5B and hSTAT5BN642H in the hematopoietic system and selected the lines B6N-Tg(STAT5B)731Biat (EMMA ID EM:12476) and B6N-Tg(STAT5BN/H)726Biat (this one; EMMA ID EM:12475), respectively, for further experiments. The hSTAT5BN642H construct was generated using overlapping PCR technology. |
| Phenotypic information | Homozygous:Unknown; homozygous animals were not produced.Heterozygous:hSTAT5BN642H mice develop an aggressive CD8+ T cell lymphoma at the age of 6-12 weeks. This goes in line with a massive expansion of spleen and lymphonodes, as well as organ infiltrations. For further details see Pham HTT et al., 2018. The heterozygous B6N Tg(STAT5B)731Biat line (EMMA ID EM:12476) exhibits no obvious phenotype and is used as an experimental control. |
| Breeding history | Less than 10 generations of backcross to C57BL/6N. |
| References |
|
| Homozygous fertile | not known |
| Homozygous viable | not known |
| Homozygous matings required | no |
| Immunocompromised | no |
Information from EMMA
| Archiving centre | University of Veterinary Medicine, Vienna, Austria |
| Animals used for archiving | heterozygous C57BL/6N |
Disease and phenotype information
MGI allele-associated human disease models
Literature references
- STAT5BN642H is a driver mutation for T cell neoplasia.;Pham Ha Thi Thanh, Maurer Barbara, Prchal-Murphy Michaela, Grausenburger Reinhard, Grundschober Eva, Javaheri Tahereh, Nivarthi Harini, Boersma Auke, Kolbe Thomas, Elabd Mohamed, Halbritter Florian, Pencik Jan, Kazemi Zahra, Grebien Florian, Hengstschläger Markus, Kenner Lukas, Kubicek Stefan, Farlik Matthias, Bock Christoph, Valent Peter, Müller Mathias, Rülicke Thomas, Sexl Veronika, Moriggl Richard, ;2018;The Journal of clinical investigation;128;387-401; 29200404